These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22496265)

  • 1. Association of treatment with losartan vs candesartan and mortality among patients with heart failure.
    Svanström H; Pasternak B; Hviid A
    JAMA; 2012 Apr; 307(14):1506-12. PubMed ID: 22496265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of candesartan vs losartan with all-cause mortality in patients with heart failure.
    Eklind-Cervenka M; Benson L; Dahlström U; Edner M; Rosenqvist M; Lund LH
    JAMA; 2011 Jan; 305(2):175-82. PubMed ID: 21224459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
    Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
    Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan vs candesartan for heart failure.
    Lund LH; Benson L
    JAMA; 2012 Jul; 308(4):336; author reply 336-7. PubMed ID: 22820775
    [No Abstract]   [Full Text] [Related]  

  • 7. [Remarkable results with candesartan].
    Rutten FH; Groenwold RH
    Ned Tijdschr Geneeskd; 2011; 155():A3313. PubMed ID: 21504640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan vs losartan and mortality in patients with heart failure.
    Kaplan N
    JAMA; 2011 Apr; 305(15):1541; author reply 1541-2. PubMed ID: 21505132
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
    Desai RJ; Ashton CM; Deswal A; Morgan RO; Mehta HB; Chen H; Aparasu RR; Johnson ML
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):233-40. PubMed ID: 21786364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
    Kjeldsen SE; Stålhammar J; Hasvold P; Bodegard J; Olsson U; Russell D
    J Hum Hypertens; 2010 Apr; 24(4):263-73. PubMed ID: 19890371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Suzuki H; Kanno Y;
    Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
    Ariti CA; Cleland JG; Pocock SJ; Pfeffer MA; Swedberg K; Granger CB; McMurray JJ; Michelson EL; Ostergren J; Yusuf S
    Am Heart J; 2011 Nov; 162(5):900-6. PubMed ID: 22093207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
    Selmer C; Lamberts M; Kristensen SL; von Kappelgaard LM; Køber L; Gislason GH; Torp-Pedersen C
    Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1281-7. PubMed ID: 24962821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
    Nakamura T; Kanno Y; Takenaka T; Suzuki H;
    Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.
    Konstam MA; Neaton JD; Dickstein K; Drexler H; Komajda M; Martinez FA; Riegger GA; Malbecq W; Smith RD; Guptha S; Poole-Wilson PA;
    Lancet; 2009 Nov; 374(9704):1840-8. PubMed ID: 19922995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.